» Articles » PMID: 23768520

Diagnostic and Outcome Differences Between Heterosexual and Nonheterosexual Men Treated for Prostate Cancer

Overview
Journal Urology
Specialty Urology
Date 2013 Jun 18
PMID 23768520
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine if heterosexual and nonheterosexual men treated for prostate cancer differ in diagnostic and treatment outcomes and in various measures of physical health, sexual function, and well being, before and after the treatment.

Methods: Four hundred sixty self-identified heterosexual and 96 self-identified nonheterosexual men completed an anonymous online survey. The men in the 2 groups were then compared using logistic regressions that controlled for differences among countries.

Results: There were no significant differences in age at diagnosis for men in the 2 groups. However, Gleason scores at diagnosis were significantly lower for the nonheterosexual men (P = .02). There were no significant differences among men in the 2 groups in the proportion who receive different treatment modalities or in the incidence of urinary incontinence, who experience bone pain (as a marker of disease progression), who take antidepressants (as a proxy measure for mental health), or who experience erectile dysfunction after the treatment. However, nonheterosexual men rated the degree to which they were bothered by an inability to ejaculate significantly higher than did the heterosexual men (P = .04).

Conclusion: This is the first set of findings from a survey that compares heterosexual and nonheterosexual men treated for prostate cancer. Although the groups were generally similar, nonheterosexual men might experience more intensive screening for disease, as indicated by lower Gleason scores at diagnosis. Nonheterosexual men appear more distressed by loss of ejaculation after prostatectomy.

Citing Articles

Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer.

Dickstein D, Edwards C, Lehrer E, Tarras E, Gallitto M, Sfakianos J Nat Rev Urol. 2023; 20(6):332-355.

PMID: 37217695 PMC: 10389287. DOI: 10.1038/s41585-023-00778-3.


Development of a Training to Address Needs of Sexual and Gender Minority Prostate Cancer Survivors: Results of Formative Research.

Pratt-Chapman M, Goltz H, Latini D, Goeren W, Suarez R, Zhang Y J Oncol Navig Surviv. 2023; 11(9):303-309.

PMID: 37205170 PMC: 10190170.


Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life.

Yazdanpanah O, Benjamin D, Kalebasty A Cancers (Basel). 2023; 15(9).

PMID: 37174119 PMC: 10177609. DOI: 10.3390/cancers15092654.


LGBTQI cancer patients' quality of life and distress: A comparison by gender, sexuality, age, cancer type and geographical remoteness.

Ussher J, Allison K, Perz J, Power R Front Oncol. 2022; 12:873642.

PMID: 36203463 PMC: 9530284. DOI: 10.3389/fonc.2022.873642.


Let's talk about sex: tailoring prostate-cancer care for LGBT+ people.

Photopoulos J Nature. 2022; 609(7927):S48-S50.

PMID: 36104414 DOI: 10.1038/d41586-022-02864-9.